Literature DB >> 36243845

Control of CD4+ T Cell Differentiation and Function by PI3K Isoforms.

Benjamin Cameron1, Syed Aymaan Zaheer1, Margarita Dominguez-Villar2.   

Abstract

The phosphoinositide-3-kinase (PI3K) pathway is a highly conserved intracellular signaling pathway involving numerous key effectors which, in response to diverse extracellular stimuli, modulate the phenotype and function of most mammalian cell types in a pleiotropic manner. PI3K signaling plays a critical role in the development, activation, and differentiation of lymphocytes. In particular, the PI3Kδ and PI3Kγ isoforms have been shown to carry out essential, non-redundant roles in T cells, and therefore, tight regulation of the PI3K pathway is important to maintain the balance between immune tolerance and inflammation. Recent and ongoing efforts to manipulate the biology of T helper cell subsets in the treatment of autoimmune conditions, inflammatory disorders, as well as cancer have shown promising results, and targeting the PI3K pathway may be beneficial in these contexts. However, more insight as to the precise function of individual PI3K isoforms in pathogenic and protective immune cell subsets is still required, and how exactly PI3K signaling is regulated and integrated with classical immune pathways. This chapter provides an overview of the role of PI3K isoforms in the differentiation and function of T helper cell subsets, within the broader context of targeting this pathway to potentially alleviate immunopathology.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Autoimmunity; CD4+ T cells; Differentiation; Helper T cells; Inflammation; PI3K isoforms; Phosphoinositide-3-kinase; mTOR

Mesh:

Substances:

Year:  2022        PMID: 36243845     DOI: 10.1007/978-3-031-06566-8_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.737


  110 in total

1.  PI3Kγ deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome.

Authors:  Luciana Berod; Christina Heinemann; Sylvia Heink; Angelika Escher; Christine Stadelmann; Sebastian Drube; Reinhard Wetzker; Johannes Norgauer; Thomas Kamradt
Journal:  Eur J Immunol       Date:  2011-02-01       Impact factor: 5.532

2.  Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells.

Authors:  Julia Bier; Geetha Rao; Kathryn Payne; Henry Brigden; Elise French; Simon J Pelham; Anthony Lau; Helen Lenthall; Emily S J Edwards; Joanne M Smart; Theresa S Cole; Sharon Choo; Avni Y Joshi; Roshini S Abraham; Michael O'Sullivan; Kaan Boztug; Isabelle Meyts; Paul E Gray; Lucinda J Berglund; Peter Hsu; Melanie Wong; Steven M Holland; Luigi D Notarangelo; Gulbu Uzel; Cindy S Ma; Robert Brink; Stuart G Tangye; Elissa K Deenick
Journal:  J Allergy Clin Immunol       Date:  2019-02-06       Impact factor: 10.793

3.  Human TIM-1 associates with the TCR complex and up-regulates T cell activation signals.

Authors:  Lauri L Binné; Martin L Scott; Paul D Rennert
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

4.  Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.

Authors:  Shamim Ahmad; Rasha Abu-Eid; Rajeev Shrimali; Mason Webb; Vivek Verma; Atbin Doroodchi; Zuzana Berrong; Raed Samara; Paulo C Rodriguez; Mikayel Mkrtichyan; Samir N Khleif
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

5.  ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.

Authors:  L Aragoneses-Fenoll; M Montes-Casado; G Ojeda; Y Y Acosta; J Herranz; S Martínez; C Blanco-Aparicio; G Criado; J Pastor; U Dianzani; P Portolés; J M Rojo
Journal:  Biochem Pharmacol       Date:  2016-02-13       Impact factor: 5.858

6.  The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes.

Authors:  Jamil Azzi; Robert F Moore; Wassim Elyaman; Marwan Mounayar; Najib El Haddad; Sunmi Yang; Mollie Jurewicz; Ayumi Takakura; Alessandra Petrelli; Paolo Fiorina; Thomas Ruckle; Reza Abdi
Journal:  Diabetes       Date:  2012-03-08       Impact factor: 9.461

Review 7.  Cellular and Molecular Dynamics of Th17 Differentiation and its Developmental Plasticity in the Intestinal Immune Response.

Authors:  Suniti Bhaumik; Rajatava Basu
Journal:  Front Immunol       Date:  2017-03-31       Impact factor: 7.561

8.  T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.

Authors:  Laura Aragoneses-Fenoll; Gloria Ojeda; María Montes-Casado; Yeny Acosta-Ampudia; Umberto Dianzani; Pilar Portolés; José M Rojo
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

9.  Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation.

Authors:  Isabela Alcázar; Miriam Marqués; Amit Kumar; Emilio Hirsch; Matthias Wymann; Ana C Carrera; Domingo F Barber
Journal:  J Exp Med       Date:  2007-11-06       Impact factor: 14.307

10.  Germline-activating mutations in PIK3CD compromise B cell development and function.

Authors:  Danielle T Avery; Alisa Kane; Tina Nguyen; Anthony Lau; Akira Nguyen; Helen Lenthall; Kathryn Payne; Wei Shi; Henry Brigden; Elise French; Julia Bier; Jana R Hermes; David Zahra; William A Sewell; Danyal Butt; Michael Elliott; Kaan Boztug; Isabelle Meyts; Sharon Choo; Peter Hsu; Melanie Wong; Lucinda J Berglund; Paul Gray; Michael O'Sullivan; Theresa Cole; Steven M Holland; Cindy S Ma; Christoph Burkhart; Lynn M Corcoran; Tri Giang Phan; Robert Brink; Gulbu Uzel; Elissa K Deenick; Stuart G Tangye
Journal:  J Exp Med       Date:  2018-07-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.